Nice rejects another breast cancer drug


The National Institute for Health and Clinical Excellence (Nice) has banned another breast cancer drug from routine NHS use.

Cancer charities have greeted the move with disappointment and said drugs of this type are "particularly valuable". The drug fulvestrant (known commercially as Faslodex and manufactured by AstraZeneca) is used to delay the growth of a certain type of breast cancer and has previously been rejected for other types of breast cancer. But Nice's draft guidance said it does not believe the evidence submitted by the drug's manufacturer proves it works significantly better than existing treatments and so its widespread use would not be a good use of resources. The body said the evidence th...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes



Already a Professional Adviser member?


More on PMI


Bupa rolls out full mental health cover to individual market

Time limits removed

Adam Saville
clock 07 June 2019 • 1 min read

VitalityHealth launches 'comprehensive' mental health package

Unlimited CBT and counselling

Adam Saville
clock 07 February 2019 • 2 min read

April UK withdraws from UK health insurance market

'Existing PMI customers will require advice'

Adam Saville
clock 19 July 2018 • 1 min read